Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry

Haematologica. 2024 Nov 1;109(11):3745-3750. doi: 10.3324/haematol.2023.284786.
No abstract available

Grants and funding

Funding: The DESCAR-T registry was partly funded by Gilead. However, they did not participate in study design, data collection, statistical analysis or interpretation, and they did not provide assistance for manuscript writing or editorial support.